Background: COVID-19 is a global pandemic caused by SARS_COV2. The symptoms of covid-19 include: fever, dyspnea, fatigue, a recent loss of smell and taste, sore throat, cough, and cutaneous lesions. In addition, some skin manifestations were reported to be associated with COVID-19.

Methods: The study design is a descriptive cross-sectional hospital-based study. The study aimed to evaluate the level of knowledge and practice about skin manifestations of COVID-19 among doctors working at Khartoum dermatology and venereology teaching hospital. A self-administrated questionnaire was used for data collection after an informed consent was taken.

Results: Among 140 doctors working in the dermatology and venereology teaching hospital, 75.7% of the doctors had knowledge that COVID-19 can present with skin manifestations. The study results showed that about half of the participants have poor knowledge about COVID-19 skin manifestations while 25% have no knowledge, and that 35 (25%) doctors have good knowledge. From a total of 140 doctors; 46.4% reported that when patients present with COVID-19 skin lesions, they will isolate them in separate rooms and call the epidemiology center, whereas, 61 doctors (43.6%) did not know if they have a protocol for COVID-19 suspected cases. This study reported a significant association between job category and level of knowledge toward COVID-19 skin manifestations measured by Chi-square test, the P-value was 0.003 (significant at 0.05), and the same significant association was found between the year of rotation and knowledge.

Conclusion: Half of the doctors covered by this study had poor knowledge about COVID-19 skin manifestations, and therefore, educating doctors in dermatology hospitals about skin manifestations of COVID-19 is recommended, besides clear and precise guidelines and protocols for diagnosis and management.

[1] Li, H., Liu, S.-M., Yu, X.-H., Tang, S.-L., & Tang, C.-K. (2020). Coronavirus disease 2019 (COVID-19): Current status and future perspectives. International Journal of Antimicrobial Agents, 55(5), 105951. https://doi.org/10.1016/j.ijantimicag.2020.105951

[2] Guo, Y.-R., Cao, Q.-D., Hong, Z.-S., Tan, Y.-Y., Chen, S.-D., Jin, H.-J., Tan, K.-S., Wang, D.-Y., & Yan, Y. (2020). The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak–An update on the status. Military Medical Research, 7(1), 1–10. https://doi.org/10.1186/s40779- 020-00240-0

[3] WHO. Coronavirus disease 2019 (COVID-19) Situation Report – 51. Report Geneva: World Health Organization.

[4] Singhal, T. (2020). A review of coronavirus disease- 2019 (COVID-19). Indian Journal of Pediatrics, 87(4), 281–286. https://doi.org/10.1007/s12098-020- 03263-6

[5] Marzano, A. V., Cassano, N., Genovese, G., Moltrasio, C., & Vena, G. A. (2020). Cutaneous manifestations in patients with COVID-19: A preliminary review of an emerging issue. British Journal of Dermatology, 183(3), 431–442. https://doi.org/10.1111/bjd.19264

[6] Joob, B., & Wiwanitkit, V. (2020). COVID-19 in medical personnel: Observation from Thailand. The Journal of Hospital Infection, 104(4), 453. https://doi.org/10.1016/j.jhin.2020.02.016

[7] Freeman, E. E., McMahon, D. E., Lipoff, J. B., Rosenbach, M., Kovarik, C., Takeshita, J., French, L. E., Thiers, B. H., Hruza, G. J., Fox, L. P., & the American Academy of Dermatology Ad Hoc Task Force on COVID-19. (2020). Pernio-like skin lesions associated with COVID-19: A case series of 318 patients from 8 countries. Journal of the American Academy of Dermatology, 83(2), 486– 492. https://doi.org/10.1016/j.jaad.2020.05.109

[8] Sachdeva, M., Gianotti, R., Shah, M., Bradanini, L., Tosi, D., Veraldi, S., Ziv, M., Leshem, E., & Dodiuk- Gad, R. P. (2020). Cutaneous manifestations of COVID-19: Report of three cases and a review of literature. Journal of Dermatological Science, 98(2), 75–81. https://doi.org/10.1016/j.jdermsci.2020.04.011

[9] Garg, S., Garg, M., Prabhakar, N., Malhotra, P., & Agarwal, R. (2020). Unraveling the mystery of Covid-19 cytokine storm: From skin to organ systems. Dermatologic Therapy, 33(6), e13859. https://doi.org/10.1111/dth.13859

[10] Suchonwanit, P., Leerunyakul, K., & Kositkuljorn, C. (2020). Diagnostic and prognostic values of cutaneous manifestations in COVID-19. Dermatologic Therapy, 33, e13650. https://doi.org/10.1111/dth.13650

[11] Rizzetto, G., Diotallevi, F., Campanati, A., Radi, G., Bianchelli, T., Molinelli, E., Mazzanti, S., & Offidani, A. (2021). Telogen effluvium related to post severe Sars-Cov-2 infection: Clinical aspects and our management experience. Dermatologic Therapy, 34(1), e14547. https://doi.org/10.1111/dth.14547

[12] Rezigalla, A. A. (2020). Observational study designs: Synopsis for selecting an appropriate study design. Cureus, 12(1), e6692. https://doi.org/10.7759/cureus.6692

[13] Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., Xia, J., Yu, T., Zhang, X., & Zhang, L. (2020). Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet, 395(10223), 507–513. https://doi.org/10.1016/S0140-6736(20)30211-7

[14] Recalcati, S. (2020). Cutaneous manifestations in COVID-19: A first perspective. Journal of the European Academy of Dermatology and Venereology, 34(5), e212–e213. https://doi.org/10.1111/jdv.16387